Enrolling by invitationPhase 1NCT07149454
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
Studying Tetanus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
- Principal Investigator
- Jianchang HeYunnan Provincial Hospital of Traditional Chinese Medicine
- Intervention
- Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection(drug)
- Enrollment
- 68 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Lanzhou Institute of Biological Products Co., Ltd., Lanzhou, Gansu, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07149454 on ClinicalTrials.govOther trials for Tetanus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07107932A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following InjuryZhuhai Trinomab Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06635798A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionGenrix (Shanghai) Biopharmaceutical Co., Ltd.